Clinical trial · Observational
A Training Set for the HRD Model in EOC
A Training Set for the Homologous Recombination Deficiency Scoring Model With Loss of Heterozygosity Status in Epithelial Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BRCA Mutation | — | UNRESOLVED | — |
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Homologous Recombination Deficiency | — | UNRESOLVED | — |
| Loss of Heterozygosity | — | UNRESOLVED | — |
| Platinum Resistance | — | UNRESOLVED | — |
| Prognosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Homologous recombination deficiency model | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Epithelial ovarian cancer patients sensitive to platinum based chemotherapy
- interventionNames
- Genetic: Homologous recombination deficiency model
- label
- Epithelial ovarian cancer patients resistant to platinum based chemotherapy
- interventionNames
- Genetic: Homologous recombination deficiency model
Primary outcomes (1)
- measure
- Homologous recombination deficiency (HRD) score
- timeFrame
- Two years
- description
- The HRD score for individual patient is a scale describing her HRD status. The score model is calculated by the analysis for loss of heterozygosity (LOH), and the minimum value is 0, but the maximun value is not available. Higher scores mean more sensitivity to poly-ADP-ribose polymerase inhibitor
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older * Pathological confirmation of epithelial ovarian cancer * With available tumor tissues * Given consents to participate the study Exclusion Criteria: • Not meeting all of the inclusion criteria
References
Publications (0)
Data not yet available